Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

OptimizeRx (OPRX) Equity Ratio: 2010-2025

Historic Equity Ratio for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to 0.72.

  • OptimizeRx's Equity Ratio rose 360.04% to 0.72 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.18, marking a year-over-year increase of 984.98%. This contributed to the annual value of 0.68 for FY2024, which is 95.76% down from last year.
  • As of Q3 2025, OptimizeRx's Equity Ratio stood at 0.72, which was up 360.04% from 0.7 recorded in Q2 2025.
  • OptimizeRx's 5-year Equity Ratio high stood at 0.96 for Q1 2021, and its period low was 0.68 during Q4 2024.
  • Over the past 5 years, OptimizeRx's median Equity Ratio value was 0.94 (recorded in 2022), while the average stood at 0.84.
  • As far as peak fluctuations go, OptimizeRx's Equity Ratio surged by 2311.03% in 2021, and later tumbled by 2666.81% in 2024.
  • OptimizeRx's Equity Ratio (Quarter) stood at 0.93 in 2021, then increased by 0.51% to 0.94 in 2022, then fell by 26.31% to 0.69 in 2023, then dropped by 0.96% to 0.68 in 2024, then grew by 5.02% to 0.72 in 2025.
  • Its Equity Ratio was 0.72 in Q3 2025, compared to 0.7 in Q2 2025 and 0.69 in Q1 2025.